Evidence map›Paper›PMID 36251340›Full record

ArticleCancer2022

Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression.

Susan K Lutgendorf, Premal H Thaker, Michael J Goodheart, Jesusa M G Arevalo, Mamur A Chowdhury, Alyssa E Noble, Laila Dahmoush, George M Slavich, Frank J Penedo, Anil K Sood and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Susan K LutgendorfDepartment of Psychological and Brain Sciences, University of Iowa, Iowa City, Iowa, USA.ORCID 0000-0003-3793-5881
Premal H ThakerDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, USA.
Michael J GoodheartHolden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA.
Jesusa M G ArevaloDivision of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Mamur A ChowdhuryDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alyssa E NobleDepartment of Psychological and Brain Sciences, University of Iowa, Iowa City, Iowa, USA.
Laila DahmoushDepartment of Pathology, University of Iowa, Iowa City, Iowa, USA.
George M SlavichCousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, California, USA.
Frank J PenedoDepartment of Psychology and Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-4242-1762
Steven W ColeDivision of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
University of Iowa · USUniversity of California, Los Angeles · USThe University of Texas MD Anderson Cancer Center · USUniversity of Miami · USWashington University in St. Louis · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
Harnessing the power of exosomes for non-coding RNA deliveryR35CA209904 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2023
$5.0M
Ovarian Cancer: Mechanisms of Neuroendocrine RegulationR01CA109298 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2005 to 2017
$4.5M
Behavioral Influences on Ovarian Cancer Progression: Role of ChemoresistanceR01CA193249 · NCI · UNIVERSITY OF IOWA · PI LUTGENDORF, SUSAN K · 2016 to 2020
$3.2M
Biobehavioral Influences and the Ovarian Tumor MicroenvironmentR01CA140933 · NCI · UNIVERSITY OF IOWA · PI LUTGENDORF, SUSAN K · 2009 to 2013
$2.8M
NCI NIH HHS CA109298NCI NIH HHS CA209904NCI NIH HHS P30 CA086862NCI NIH HHS P30CA086862NCI NIH HHS R01 CA109298NCI NIH HHS R01 CA140933NCI NIH HHS R01 CA193249NCI NIH HHS R35 CA209904
6 · The paper itself

Abstract

backgroundBiobehavioral factors such as social isolation and depression have been associated with disease progression in ovarian and other cancers. Here, the authors developed a noninvasive, exosomal RNA profile for predicting ovarian cancer disease progression and subsequently tested whether it increased in association with biobehavioral risk factors.

methodsExosomes were isolated from plasma samples from 100 women taken before primary surgical resection or neoadjuvant (NACT) treatment of ovarian carcinoma and 6 and 12 months later. Biobehavioral measures were sampled at all time points. Plasma from 76 patients was allocated to discovery analyses in which morning presurgical/NACT exosomal RNA profiles were analyzed by elastic net machine learning to identify a biomarker predicting rapid (≤6 months) versus more extended disease-free intervals following initial treatment. Samples from a second subgroup of 24 patients were analyzed by mixed-effects linear models to determine whether the progression-predictive biomarker varied longitudinally as a function of biobehavioral risk factors (social isolation and depressive symptoms).

resultsAn RNA-based molecular signature was identified that discriminated between individuals who had disease progression in ≤6 months versus >6 months, independent of clinical variables (age, disease stage, and grade). In a second group of patients analyzed longitudinally, social isolation and depressive symptoms were associated with upregulated expression of the disease progression propensity biomarker, adjusting for covariates.

conclusionThese data identified a novel exosome-derived biomarker indicating propensity of ovarian cancer progression that is sensitive to biobehavioral variables. This derived biomarker may be potentially useful for risk assessment, intervention targeting, and treatment monitoring.

Indexed as

CarcinomaExosomesOvarian NeoplasmsBiomarkersCarcinoma, Ovarian EpithelialDisease ProgressionFemaleHumansRNABiomarkersRNAbiobehavioralexosomeovarian cancerprogressionsocial supporttranscriptome

Identifiers

PMID36251340
PMCPMC9744596
OpenAlexW4306663327

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.